$CVS
CVS HEALTH Corp Stock $cvs

$cvs Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000006480320000015 Filed on May 06, 2020

Income Statement

Concept	2020 Q1	2019 Q4	2019 Q1
Revenue	$66.76B	$66.89B	$61.65B
YoY Change	8.29%	22.9%	34.77%
Cost Of Revenue	$40.35B	$42.07B	$37.25B
YoY Change	8.32%	10.22%	-0.69%
Gross Profit	$26.41B	$24.82B	$24.40B
YoY Change	8.23%	48.26%	196.18%
Gross Profit Margin	39.56%	37.11%	39.58%
Selling, General & Admin	$8.494B	$8.394B	$8.142B
YoY Change	4.32%	26.93%	65.72%
% of Gross Profit	32.16%	33.81%	33.37%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.086B		$1.111B
YoY Change	-2.25%		72.52%
% of Gross Profit	4.11%		4.55%
Operating Expenses	$8.563B	$21.53B	$8.250B
YoY Change	3.79%	63.0%	67.92%
Operating Profit	$3.458B	$3.037B	$2.690B
YoY Change	28.55%	268.57%	34.77%
Interest Expense	$733.0M	-$734.0M	$782.0M
YoY Change	-6.27%	-39.74%	49.52%
% of Operating Profit	21.2%	-24.17%	29.07%
Other Income/Expense, Net	$54.00M	$31.00M	$31.00M
YoY Change	74.19%	181.82%	933.33%
Pretax Income	$2.779B	$2.334B	$1.939B
YoY Change	43.32%	2188.24%	31.9%
Income Tax	$767.0M	$590.0M	$512.0M
% Of Pretax Income	27.6%	25.28%	26.41%
Net Earnings	$2.007B	$1.747B	$1.421B
YoY Change	41.24%	-516.95%	42.38%
Net Earnings / Revenue	3.01%	2.61%	2.31%
Basic Earnings Per Share	$1.54	$1.34	$1.09
Diluted Earnings Per Share	$1.53	$1.33	$1.09
COMMON SHARES
Basic Shares Outstanding	1.306B shares	1.301B shares	1.298B shares
Diluted Shares Outstanding	1.312B shares		1.302B shares

Balance Sheet

Concept	2020 Q1	2019 Q4	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.71B	$8.056B	$8.322B
YoY Change	52.76%	25.52%	-80.25%
Cash & Equivalents	$10.08B	$5.683B	$5.896B
Short-Term Investments	$2.632B	$2.373B	$2.426B
Other Short-Term Assets	$6.232B	$5.113B	$4.533B
YoY Change	37.48%	11.61%	422.24%
Inventory	$16.98B	$17.52B	$15.45B
Prepaid Expenses
Receivables	$23.04B	$19.62B	$19.51B
Other Receivables	$2.838B	$2.381B	$868.0M
Total Short-Term Assets	$58.96B	$50.30B	$45.20B
YoY Change	30.45%	11.18%	-37.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.15B	$12.04B	$11.36B
YoY Change	6.92%	6.12%	11.99%
Goodwill	$79.99B	$79.75B	$79.08B
YoY Change	1.16%	1.36%
Intangibles	$32.73B	$33.12B	$36.31B
YoY Change	-9.86%	-9.32%
Long-Term Investments	$16.84B	$17.31B	$16.41B
YoY Change	2.62%	10.06%
Other Assets	$4.748B	$4.600B	$4.525B
YoY Change	4.93%	-8.84%	167.12%
Total Long-Term Assets	$171.7B	$172.1B	$171.5B
YoY Change	0.12%	13.84%	170.71%
TOTAL ASSETS
Total Short-Term Assets	$58.96B	$50.30B	$45.20B
Total Long-Term Assets	$171.7B	$172.1B	$171.5B
Total Assets	$230.6B	$222.4B	$216.7B
YoY Change	6.45%	13.23%	60.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$33.26B	$30.97B	$26.82B
YoY Change	24.01%	17.15%	41.28%
Accrued Expenses	$13.57B	$12.13B	$10.66B
YoY Change	27.35%	13.28%	38.0%
Deferred Revenue	$85.00M	$73.00M	$75.00M
YoY Change	13.33%	8.96%
Short-Term Debt	$255.0M	$0.00	$3.005B
YoY Change	-91.51%	-100.0%
Long-Term Debt Due	$5.828B	$3.781B	$1.267B
YoY Change	359.98%	198.89%	-64.23%
Total Short-Term Liabilities	$59.56B	$53.30B	$45.76B
YoY Change	30.15%	21.12%	51.29%
LONG-TERM LIABILITIES
Long-Term Debt	$65.74B	$64.70B	$71.35B
YoY Change	-7.87%	-9.44%	15.91%
Other Long-Term Liabilities	$2.117B	$2.162B	$2.262B
YoY Change	-6.41%	-22.23%	41.02%
Total Long-Term Liabilities	$67.85B	$66.86B	$73.61B
YoY Change	-7.82%	-9.92%	16.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$59.56B	$53.30B	$45.76B
Total Long-Term Liabilities	$67.85B	$66.86B	$73.61B
Total Liabilities	$165.2B	$158.3B	$157.9B
YoY Change	4.57%	14.77%	63.73%
SHAREHOLDERS EQUITY
Retained Earnings	$46.46B	$45.11B	$41.09B
YoY Change	13.06%	10.26%
Common Stock	$17.00M	$17.00M	$17.00M
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$28.18B	$28.24B	$28.22B
YoY Change	-0.14%	0.02%
Treasury Stock Shares	424.0M shares	425.0M shares	424.0M shares
Shareholders Equity	$65.14B	$63.86B	$58.40B
YoY Change
Total Liabilities & Shareholders Equity	$230.6B	$222.4B	$219.8B
YoY Change	4.95%	13.23%	62.62%

Cashflow Statement

Concept	2020 Q1	2019 Q4	2019 Q1
OPERATING ACTIVITIES
Net Income	$2.007B	$1.747B	$1.421B
YoY Change	41.24%	-516.95%	42.38%
Depreciation, Depletion And Amortization	$1.086B		$1.111B
YoY Change	-2.25%		72.52%
Cash From Operating Activities	$3.305B	$2.634B	$1.948B
YoY Change	69.66%	6.25%	-17.28%
INVESTING ACTIVITIES
Capital Expenditures	$742.0M	-$567.0M	$716.0M
YoY Change	3.63%	-3.08%	48.55%
Acquisitions	$613.0M		$124.0M
YoY Change	394.35%		-64.87%
Other Investing Activities	-$5.000M	-$142.0M	-$10.00M
YoY Change	-50.0%	-99.66%	-600.0%
Cash From Investing Activities	-$1.597B	-$709.0M	-$891.0M
YoY Change	79.24%	-98.31%	580.15%
FINANCING ACTIVITIES
Cash Dividend Paid	$652.0M		$649.0M
YoY Change	0.46%		27.76%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$1.008B		$882.0M
YoY Change	14.29%		88100.0%
Cash From Financing Activities	$2.675B	-1.440B	$816.0M
YoY Change	227.82%	-176.11%	-97.86%
NET CHANGE
Cash From Operating Activities	$3.305B	2.634B	$1.948B
Cash From Investing Activities	-$1.597B	-709.0M	-$891.0M
Cash From Financing Activities	$2.675B	-1.440B	$816.0M
Net Change In Cash	$4.383B	485.0M	$1.873B
YoY Change	134.01%	-101.29%	-95.36%
FREE CASH FLOW
Cash From Operating Activities	$3.305B	$2.634B	$1.948B
Capital Expenditures	$742.0M	-$567.0M	$716.0M
Free Cash Flow	$2.563B	$3.201B	$1.232B
YoY Change	108.04%	4.47%	-34.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2018Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1727000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1729000000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1302000000	shares
CY2019Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2018Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	USD
CY2019Q1	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	USD
CY2019Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	USD
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000064803
CY2019Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.5
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1305000000	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	17000000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	17000000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	17000000	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000.0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000.0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2020Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	425000000	shares
CY2020Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	424000000	shares
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-01011
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	CVS HEALTH CORPORATION
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	One CVS Drive,
CY2019Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Woonsocket,
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	RI
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02895
CY2020Q1	dei	City Area Code CityAreaCode	(401)
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	765-1500
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	05-0494040
CY2020Q1	dei	Trading Symbol TradingSymbol	CVS
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1307090830	shares
CY2020Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	17640000000	USD
CY2019Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	16282000000	USD
CY2020Q1	us-gaap	Net Investment Income NetInvestmentIncome	162000000	USD
CY2019Q1	us-gaap	Net Investment Income NetInvestmentIncome	249000000	USD
CY2020Q1	us-gaap	Revenues Revenues	66755000000	USD
CY2019Q1	us-gaap	Revenues Revenues	61646000000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	40347000000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	37247000000	USD
CY2020Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	14387000000	USD
CY2019Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	13459000000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	8563000000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	8250000000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	63297000000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	58956000000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3458000000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2690000000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	733000000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	782000000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	54000000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31000000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2779000000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1939000000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	767000000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	512000000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	2012000000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	1427000000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5000000	USD
CY2019Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	6000000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	2007000000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	1421000000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.54
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.53
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.09
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1306000000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1298000000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1312000000	shares
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-332000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	331000000	USD
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1302000000	shares
CY2020Q1	us-gaap	Profit Loss ProfitLoss	2012000000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	1427000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-311000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-4000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	334000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-12000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-9000000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1680000000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1758000000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5000000	USD
CY2019Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	6000000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1675000000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1752000000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10081000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5683000000	USD
CY2020Q1	us-gaap	Short Term Investments ShortTermInvestments	2632000000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	2373000000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23037000000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19617000000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	16976000000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	17516000000	USD
CY2020Q1	us-gaap	Other Assets Current OtherAssetsCurrent	6232000000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5113000000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	58958000000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	50302000000	USD
CY2020Q1	us-gaap	Long Term Investments LongTermInvestments	16840000000	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	17314000000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12146000000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12044000000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20672000000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20860000000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	79993000000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	79749000000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	32727000000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33121000000	USD
CY2020Q1	us-gaap	Separate Account Assets SeparateAccountAssets	4555000000	USD
CY2019Q4	us-gaap	Separate Account Assets SeparateAccountAssets	4459000000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4748000000	USD
CY2020Q1	us-gaap	Assets Assets	230639000000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4600000000	USD
CY2019Q4	us-gaap	Assets Assets	222449000000	USD
CY2020Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	10223000000	USD
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	10492000000	USD
CY2020Q1	cvs	Pharmacy Claimsand Discounts Payable Current PharmacyClaimsandDiscountsPayableCurrent	15449000000	USD
CY2019Q4	cvs	Pharmacy Claimsand Discounts Payable Current PharmacyClaimsandDiscountsPayableCurrent	13601000000	USD
CY2020Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	7585000000	USD
CY2019Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	6879000000	USD
CY2020Q1	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	3110000000	USD
CY2019Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	2991000000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13574000000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12133000000	USD
CY2020Q1	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1774000000	USD
CY2019Q4	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1830000000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1762000000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1596000000	USD
CY2020Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	255000000	USD
CY2019Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	5828000000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3781000000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	59560000000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	53303000000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18739000000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18926000000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	65735000000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	64699000000	USD
CY2020Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7121000000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7294000000	USD
CY2020Q1	us-gaap	Separate Accounts Liability SeparateAccountsLiability	4555000000	USD
CY2019Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	4459000000	USD
CY2020Q1	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	7338000000	USD
CY2019Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	7436000000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2117000000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2162000000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	165165000000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	158279000000	USD
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	46180000000	USD
CY2019Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	45972000000	USD
CY2020Q1	us-gaap	Treasury Stock Value TreasuryStockValue	28182000000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	28235000000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	46455000000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	45108000000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	687000000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1019000000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	65140000000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	63864000000	USD
CY2020Q1	us-gaap	Minority Interest MinorityInterest	334000000	USD
CY2019Q4	us-gaap	Minority Interest MinorityInterest	306000000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	65474000000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64170000000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230639000000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	222449000000	USD
CY2020Q1	us-gaap	Proceeds From Customers ProceedsFromCustomers	63751000000	USD
CY2019Q1	us-gaap	Proceeds From Customers ProceedsFromCustomers	58873000000	USD
CY2020Q1	cvs	Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies	36969000000	USD
CY2019Q1	cvs	Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies	35645000000	USD
CY2020Q1	cvs	Paymentsfor Insurance Benefits PaymentsforInsuranceBenefits	14303000000	USD
CY2019Q1	cvs	Paymentsfor Insurance Benefits PaymentsforInsuranceBenefits	12951000000	USD
CY2020Q1	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	8187000000	USD
CY2019Q1	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	7403000000	USD
CY2020Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	206000000	USD
CY2019Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	250000000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	1128000000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	1123000000	USD
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	65000000	USD
CY2019Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	53000000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3305000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1948000000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1288000000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1986000000	USD
CY2020Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1535000000	USD
CY2019Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2047000000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	742000000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	716000000	USD
CY2020Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	613000000	USD
CY2019Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	124000000	USD
CY2020Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-5000000	USD
CY2019Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-10000000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1597000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-891000000	USD
CY2020Q1	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	255000000	USD
CY2019Q1	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	2285000000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3946000000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1008000000	USD
CY2019Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	882000000	USD
CY2020Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	652000000	USD
CY2019Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	649000000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	154000000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	101000000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16000000	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	44000000	USD
CY2020Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-4000000	USD
CY2019Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	5000000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2675000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	816000000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4383000000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1873000000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5954000000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4295000000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10337000000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6168000000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	2012000000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	1427000000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1086000000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1111000000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	96000000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	114000000	USD
CY2020Q1	cvs	Deferredincometaxesandothernoncashitems Deferredincometaxesandothernoncashitems	-35000000	USD
CY2019Q1	cvs	Deferredincometaxesandothernoncashitems Deferredincometaxesandothernoncashitems	153000000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2715000000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1989000000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-541000000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1001000000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1119000000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	389000000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1928000000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-22000000	USD
CY2020Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	139000000	USD
CY2019Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	553000000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1372000000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-11000000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3305000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1948000000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64170000000	USD
CY2020Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	2012000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-332000000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	208000000	USD
CY2020Q1	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	-53000000	USD
CY2020Q1	us-gaap	Dividends Common Stock DividendsCommonStock	657000000	USD
CY2020Q1	cvs	Noncontrollinginterest Other Period Increase Decrease NoncontrollinginterestOtherPeriodIncreaseDecrease	23000000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	65474000000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	58543000000	USD
CY2019Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	1427000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	331000000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	175000000	USD
CY2019Q1	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	-7000000	USD
CY2019Q1	us-gaap	Dividends Common Stock DividendsCommonStock	651000000	USD
CY2019Q1	cvs	Noncontrollinginterest Other Period Increase Decrease NoncontrollinginterestOtherPeriodIncreaseDecrease	-4000000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	60006000000	USD
CY2020Q1	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2020Q1	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	17000000	USD
CY2020Q1	cvs	Numberof Pharmacy Plan Members NumberofPharmacyPlanMembers	102000000	person
CY2020Q1	cvs	Numberof Patients Servedper Year NumberofPatientsServedperYear	1000000	patient
CY2020Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	Segment
CY2020Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div>
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10081000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5683000000	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	256000000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	271000000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10337000000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5954000000	USD
CY2020Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7698000000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	6717000000	USD
CY2020Q1	cvs	Vendorand Manufacturer Receivables VendorandManufacturerReceivables	8585000000	USD
CY2019Q4	cvs	Vendorand Manufacturer Receivables VendorandManufacturerReceivables	7856000000	USD
CY2020Q1	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	3916000000	USD
CY2019Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	2663000000	USD
CY2020Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2838000000	USD
CY2019Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2381000000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23037000000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19617000000	USD
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	340000000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	319000000	USD
CY2020Q1	us-gaap	Net Investment Income NetInvestmentIncome	162000000	USD
CY2020Q1	us-gaap	Revenues Revenues	66755000000	USD
CY2019Q1	us-gaap	Net Investment Income NetInvestmentIncome	249000000	USD
CY2019Q1	us-gaap	Revenues Revenues	61646000000	USD
CY2020Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7698000000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	6717000000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	85000000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	73000000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	73000000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	67000000	USD
CY2020Q1	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	99000000	USD
CY2019Q1	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	90000000	USD
CY2020Q1	cvs	Contractwith Customer Liaiblity Redemptionand Breakage ContractwithCustomerLiaiblityRedemptionandBreakage	87000000	USD
CY2019Q1	cvs	Contractwith Customer Liaiblity Redemptionand Breakage ContractwithCustomerLiaiblityRedemptionandBreakage	82000000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	85000000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	75000000	USD
CY2020Q1	cvs	Health Insurer Fee HealthInsurerFee	271000000	USD
CY2020Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	20000000	USD
CY2019Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	10000000	USD
CY2020Q1	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	21000000	USD
CY2019Q1	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	25000000	USD
CY2020Q1	us-gaap	Short Term Investments ShortTermInvestments	2632000000	USD
CY2020Q1	us-gaap	Long Term Investments LongTermInvestments	16840000000	USD
CY2020Q1	us-gaap	Investments Investments	19472000000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	2373000000	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	17314000000	USD
CY2019Q4	us-gaap	Investments Investments	19687000000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16145000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	48000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Amortized Cost Net DebtSecuritiesAvailableForSaleAmortizedCostNet	16097000000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	866000000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	246000000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	16717000000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	15898000000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2019Q4	cvs	Debt Securities Available For Sale Amortized Cost Net DebtSecuritiesAvailableForSaleAmortizedCostNet	15898000000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1035000000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	16922000000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q1	cvs	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date Within One Year Amortized Cost Net DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNet	1219000000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1225000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Five Years Amortized Cost Net DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAmortizedCostNet	5292000000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	5399000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Maturity Allocated And Single Maturity Dateafter Five Through Ten Years Amortized Cost Net DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateafterFiveThroughTenYearsAmortizedCostNet	3135000000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	3233000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Allocated And Single Maturity Date Maturity After10 Years Amortized Cost Net DebtSecuritiesAvailableForSaleAllocatedAndSingleMaturityDateMaturityAfter10YearsAmortizedCostNet	3708000000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	4110000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Amortized Cost Net DebtSecuritiesAvailableForSaleAmortizedCostNet	16097000000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	16717000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	2947	security
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	3630000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	232000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	102	security
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	70000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	14000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	3049	security
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	3700000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	246000000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	522	security
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	982000000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	6000000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	200	security
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	187000000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	5000000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	722	security
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	1169000000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	11000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear	170000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss	3000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears	1112000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss	45000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears	837000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss	64000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears	570000000	USD
CY2020Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss	53000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	3700000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	246000000	USD
CY2020Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	206000000	USD
CY2019Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	199000000	USD
CY2020Q1	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	8000000	USD
CY2019Q1	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	9000000	USD
CY2020Q1	cvs	Investment Income Excluding Capital Gainsor Losses InvestmentIncomeExcludingCapitalGainsorLosses	198000000	USD
CY2019Q1	cvs	Investment Income Excluding Capital Gainsor Losses InvestmentIncomeExcludingCapitalGainsorLosses	190000000	USD
CY2020Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-36000000	USD
CY2019Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	59000000	USD
CY2020Q1	us-gaap	Investment Income Net InvestmentIncomeNet	162000000	USD
CY2019Q1	us-gaap	Investment Income Net InvestmentIncomeNet	249000000	USD
CY2020Q1	cvs	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings Credit Related OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarningsCreditRelated	45000000	USD
CY2020Q1	cvs	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings Yield Related OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarningsYieldRelated	41000000	USD
CY2019Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	7000000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	723000000	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1489000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	20000000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	35000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	35000000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	2000000	USD
CY2020Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table shows the components of the change in health care costs payable during the </span><span style="font-family:Times New Roman;font-size:10pt;">three months ended</span><span style="font-family:Times New Roman;font-size:10pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;"> and 2019:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;text-decoration:underline;">In millions</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Health care costs payable, beginning of the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,879</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Reinsurance recoverables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Health care costs payable, beginning of the period, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add: Components of incurred health care costs</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,764</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,804</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(446</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total incurred health care costs </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,358</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Claims paid</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,773</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,004</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,242</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,812</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total claims paid</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,015</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add: Premium deficiency reserve</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Health care costs payable, end of the period, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,581</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add: Reinsurance recoverables</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Health care costs payable, end of the period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,701</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">_____________________________________________</sup> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;vertical-align:bottom;font-size:8pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;vertical-align:bottom;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;">Total incurred health care costs for the </span><span style="font-family:Times New Roman;font-size:8pt;">three months ended</span><span style="font-family:Times New Roman;font-size:8pt;"> </span><span style="font-family:Times New Roman;font-size:8pt;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:8pt;"> and </span><span style="font-family:Times New Roman;font-size:8pt;">2019</span><span style="font-family:Times New Roman;font-size:8pt;"> in the table above exclude (i) </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$10 million</span></span><span style="font-family:Times New Roman;font-size:8pt;"> and </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$11 million</span></span><span style="font-family:Times New Roman;font-size:8pt;">, respectively, related to a premium deficiency reserve related to the Company’s Medicaid products, (ii) </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$9 million</span></span><span style="font-family:Times New Roman;font-size:8pt;"> and </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$10 million</span></span><span style="font-family:Times New Roman;font-size:8pt;">, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the Company’s unaudited condensed consolidated balance sheets and (iii) </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$68 million</span></span><span style="font-family:Times New Roman;font-size:8pt;"> and </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$80 million</span></span><span style="font-family:Times New Roman;font-size:8pt;">, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the Company’s unaudited condensed consolidated balance sheets.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div>
CY2020Q1	us-gaap	Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet	5700000000	USD
CY2020Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	255000000	USD
CY2019Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2020Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	919000000	USD
CY2019Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	808000000	USD
CY2020Q1	cvs	Debt Long Term And Short Term And Lease Obligation Combined Amount Gross DebtLongTermAndShortTermAndLeaseObligationCombinedAmountGross	72612000000	USD
CY2019Q4	cvs	Debt Long Term And Short Term And Lease Obligation Combined Amount Gross DebtLongTermAndShortTermAndLeaseObligationCombinedAmountGross	69246000000	USD
CY2020Q1	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	256000000	USD
CY2019Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	262000000	USD
CY2020Q1	cvs	Debt Instrument Unamortized Discountand Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet	1050000000	USD
CY2019Q4	cvs	Debt Instrument Unamortized Discountand Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet	1028000000	USD
CY2020Q1	cvs	Debt Long Term And Short Term And Lease Obligation Combined Amount Net DebtLongTermAndShortTermAndLeaseObligationCombinedAmountNet	71818000000	USD
CY2019Q4	cvs	Debt Long Term And Short Term And Lease Obligation Combined Amount Net DebtLongTermAndShortTermAndLeaseObligationCombinedAmountNet	68480000000	USD
CY2020Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	255000000	USD
CY2019Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2020Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	5828000000	USD
CY2019Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	3781000000	USD
CY2020Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	65735000000	USD
CY2019Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	64699000000	USD
CY2020Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	3950000000	USD
CY2020Q1	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	7000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-5000000	USD
CY2020Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-332000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	331000000	USD
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12000000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15000000	shares
CY2020Q1	us-gaap	Profit Loss ProfitLoss	2012000000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	1427000000	USD
CY2020Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	USD
CY2019Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	2000000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5000000	USD
CY2019Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	6000000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2007000000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1419000000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1306000000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1298000000	shares
CY2020Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	6000000	shares
CY2019Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	4000000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1312000000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1302000000	shares
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.54
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.53
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.09
CY2020Q1	cvs	Guarantor Obligations Numberof Leases GuarantorObligationsNumberofLeases	77	store
CY2015Q3	cvs	Loss Contingency Number Of Locations With Subpoena For Documents LossContingencyNumberOfLocationsWithSubpoenaForDocuments	8	store
CY2012	cvs	Loss Contingency Audit Methodology Sample Size LossContingencyAuditMethodologySampleSize	200	memeber
	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	6	claim
	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	6	claim
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	Segment
CY2020Q1	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	66593000000	USD
CY2020Q1	us-gaap	Net Investment Income NetInvestmentIncome	162000000	USD
CY2020Q1	us-gaap	Revenues Revenues	66755000000	USD
CY2020Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4113000000	USD
CY2019Q1	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	61397000000	USD
CY2019Q1	us-gaap	Net Investment Income NetInvestmentIncome	249000000	USD
CY2019Q1	us-gaap	Revenues Revenues	61646000000	USD
CY2019Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	3595000000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3458000000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2690000000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	586000000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	622000000	USD
CY2020Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	69000000	USD
CY2019Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	148000000	USD
CY2020Q1	cvs	Store Rationalization Charges StoreRationalizationCharges	0	USD
CY2019Q1	cvs	Store Rationalization Charges StoreRationalizationCharges	135000000	USD
CY2020Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4113000000	USD
CY2019Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	3595000000	USD

Files In Submission

Name	View Source	Status
0000064803-20-000015-index-headers.html	Edgar Link	pending
0000064803-20-000015-index.html	Edgar Link	pending
0000064803-20-000015.txt	Edgar Link	pending
0000064803-20-000015-xbrl.zip	Edgar Link	pending
a0331202010-q.htm	Edgar Link	pending
a0331202010-q_htm.xml	Edgar Link	completed
a03312020ex101.htm	Edgar Link	pending
a03312020ex151.htm	Edgar Link	pending
a03312020ex311.htm	Edgar Link	pending
a03312020ex312.htm	Edgar Link	pending
a03312020ex321.htm	Edgar Link	pending
a03312020ex322.htm	Edgar Link	pending
cvs-20200331.xsd	Edgar Link	pending
cvs-20200331_cal.xml	Edgar Link	unprocessable
cvs-20200331_def.xml	Edgar Link	unprocessable
cvs-20200331_lab.xml	Edgar Link	unprocessable
cvs-20200331_pre.xml	Edgar Link	unprocessable
cvshealtha29.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVS
CVS HEALTH Corp Stock $cvs

2020 Q1 Form 10-Q Financial Statement

#000006480320000015 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS CVS HEALTH Corp Stock $cvs

2020 Q1 Form 10-Q Financial Statement

#000006480320000015 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS
CVS HEALTH Corp Stock $cvs